Sign in
Not yet taking people in United StatesPhase 2

OEA for Young Adults With Alcohol Use Disorder

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
42 people, planned
Starts
15 Jan 2027
Expected to end
1 Jun 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • oleoylethanolamide
Record updated
17 November 2026

Who can take part

Age
18 years to 25 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show the criterionShow less

Who can take part

  • Age 18 to 25; Call study team for additional screening and information

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 25 years old?

Where in United States

  • Medical University of South CarolinaCharleston, United StatesContact: Cori Herring, BSNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the effects of oleoylethanolamide (OEA) supplementation on inflammation, the oral microbiome, neurocognitive function, and alcohol use in young adults ages 18 to 25 with alcohol use disorder (AUD). The main questions it aims to answer are:

Read full original descriptionShow less

* Does OEA reduce peripheral markers of immune activation (IL-6, TNF-α, IL-1β, and LPS)? * Does OEA alter oral microbiome composition? * Does OEA improve neurocognitive measures of reward sensitivity and impulsivity?

Researchers will compare OEA to a placebo (a look-alike substance with no active ingredient) to determine whether OEA improves biological and behavioral outcomes associated with AUD.

Participants (N = 42) will:

* Be randomly assigned to receive 300mg TRIPTI (providing 250 mg/day of OEA) or placebo for 6 weeks. * Provide blood, saliva, and urine samples * Complete cognitive testing and questionnaires * Report alcohol use during the study * Attend in-person study visits for monitoring and assessments

This randomized, double-blind, placebo-controlled pilot trial will provide preliminary data on the potential efficacy of OEA as a multi-system intervention for young adults with AUD.

The 2 groups in the trial

  • OEATreatment being tested

    Participants receive 300mg TRIPTI a day (providing 250 mg/day oleoylethanolamide \[OEA\]) orally for 6 weeks.

    Treatment: oleoylethanolamide

  • PlaceboPlacebo, for comparison

    Participants receive a matching placebo capsule orally once daily for 6 weeks.

    Treatment: oleoylethanolamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigating Oleoylethanolamide (OEA) as a Novel Multi-System Based Therapeutic for Young Adults With Alcohol Use Disorder
Criteria questions
Built from NCT07503782, who can take part
Record updated
17 November 2026